Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics business segment is developing a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma whereas the Vaccines/BioDefense business segment includes development programs for RiVax, a ricin toxin vaccine candidate; OrbeShield, a GI acute radiation syndrome therapeutic candidate; and SGX943, a melioidosis therapeutic candidate.